← Leaderboards
Aadel Chaudhuri
Washington University
$3,906,206
Attributed
$5,579,415
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,579,415 · 5
By mechanism
R01$2,583,611 · 2
R35$1,988,250 · 1
K08$646,911 · 1
U01$360,643 · 1
Top collaborators
- Christopher A Maher2 shared
- Aaron M Newman2 shared
- Russell K. Pachynski2 shared
- Jose P. Zevallos1 shared
Most similar at Washington University
Same institution · by research overlap
- Jose P. Zevallos$1,638,729
- Mary M. Zutter$12,598,946
- Hua Li$3,159,930
- Margaret A Olsen$3,586,779
- Sidharth Venkata Puram$4,377,910
Others in their field
Other Emerging Leaders on “Cell Free Dna”
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Robert Nicol · Broad Institute, Inc.$7,498,771
- Gordon M Ringold · Quadriga Biosciences, Inc.$6,041,839
- Muhammed Murtaza · Translational Genomics Research Inst$5,522,566
- Marlena Habal · Columbia University Health Sciences$5,428,816
- Crystal Mackall · Children'S Hosp Of Philadelphia$4,614,281
Research focus
Cell Free DnaCellsCessation Of LifeTissuesDna AnalysisGenome Wide MethylationDna Methylation ProfilingPlasma CellsMorbidity - Disease RateBiological MarkersImmuneResponseBloodT-LymphocyteMortalityOrganInnovationEpigenomicsMediatingTumorPublishingDetectionCause Of DeathImmune Checkpoint Blockade
Grant awards (14)
Determinants of toxicity and response to immune checkpoint blockade through integrative profiling of T cell clonal dynamics and plasma cell- free DNA$665,413
R01 · FY2025 · CA · contact PI
Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer$610,019
R01 · FY2025 · CA
Cell-free DNA epigenomics to track the dynamics of organ damage and immune exhaustion during sepsis$403,500
R35 · FY2025 · GM · contact PI
Preanalytical Validation of Circulating Tumor DNA from Surgical Drain Fluid as a marker of Postoperative Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma$360,643
U01 · FY2025 · CA
Determinants of toxicity and response to immune checkpoint blockade through integrative profiling of T cell clonal dynamics and plasma cell- free DNA$711,704
R01 · FY2024 · CA · contact PI
Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer$596,475
R01 · FY2024 · CA
Cell-free DNA epigenomics to track the dynamics of organ damage and immune exhaustion during sepsis$403,500
R35 · FY2024 · GM · contact PI
Cell-free DNA epigenomics to track the dynamics of organ damage and immune exhaustion during sepsis$393,749
R35 · FY2023 · GM · contact PI
Cell-free DNA epigenomics to track the dynamics of organ damage and immune exhaustion during sepsis$1
R35 · FY2023 · GM · contact PI
Cell-free DNA epigenomics to track the dynamics of organ damage and immune exhaustion during sepsis$393,750
R35 · FY2022 · GM · contact PI
Cell-free DNA epigenomics to track the dynamics of organ damage and immune exhaustion during sepsis$393,750
R35 · FY2021 · GM · contact PI
Cell-Free Nucleic Acids for Early Treatment Response Assessment of Hepatocellular Cancer$214,949
K08 · FY2021 · CA · contact PI
Cell-Free Nucleic Acids for Early Treatment Response Assessment of Hepatocellular Cancer$215,495
K08 · FY2020 · CA · contact PI
Cell-Free Nucleic Acids for Early Treatment Response Assessment of Hepatocellular Cancer$216,467
K08 · FY2019 · CA · contact PI